Riociguat for the Treatment of Pulmonary Arterial Hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853

Bosentan Therapy for Pulmonary Arterial Hypertension

Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Inhaled Iloprost for Severe Pulmonary Hypertension

Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing

Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096

First‐in‐child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension

Spreemann, T., Bertram, H., Happel, C. M., Kozlik-Feldmann, R. G., & Hansmann, G. (2017) · Pulmonary Circulation · doi:10.1177/2045893217743123 · Cited by 35

Nitric Oxide–Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease

Potoka, K. P., Wood, K. C., Baust, J., Bueno, M., Hahn, S. A., Vanderpool, R. R., Bachman, T. N., Mallampalli, G. M., Osei-Hwedieh, D. O., Schrott, V. M., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0292oc · Cited by 35

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Arnold, N. D., Pickworth, J. A., West, L. E., Dawson, S., Carvalho, J. A., Casbolt, H., Braithwaite, A. T., Iremonger, J., Renshall, L., Germaschewski, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13139-9 · Cited by 37

Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment

Attanasio, U., Cuomo, A., Pirozzi, F., Loffredo, S., Abete, P., Petretta, M., Marone, G., Bonaduce, D., de Paulis, A., Rossi, F. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124430 · Cited by 35

Pulmonary Arterial Hypertension Related to Connective Tissue Disease

Ahmed, S., & Palevsky, H. I. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.10.001 · Cited by 35

Cellular interplay in pulmonary arterial hypertension: Implications for new therapies

Nogueira‐Ferreira, R., Ferreira, R., & Henriques‐Coelho, T. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.030 · Cited by 35

Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension

Ploegstra, M., Arjaans, S., Zijlstra, W. M. H., Douwes, J. M., Vissia-Kazemier, T. R., Roofthooft, M. T. R., Hillege, H. L., & Berger, R. M. F. (2015) · CHEST Journal · doi:10.1378/chest.14-3066 · Cited by 35

The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood

Reiss, C., Викторович, М. И., Bischoff, V., Subramanian, H., Kehrer, L., Friebe, A., Stasch, J., Gambaryan, S. P., & Walter, U. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13286 · Cited by 35

Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation

Corris, P. A., & Degano, B. (2014) · European Respiratory Review · doi:10.1183/09059180.00007214 · Cited by 35

Phase I Safety Study of Ranolazine in Pulmonary Arterial Hypertension

Gomberg‐Maitland, M., Schilz, R. J., Mediratta, A., Addetia, K., Coslet, S., Thomeas, V., Gillies, H., & Oudiz, R. J. (2015) · Pulmonary Circulation · doi:10.1086/683813 · Cited by 36

The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review

Sandner, P., Berger, P., & Zenzmaier, C. (2016) · Gerontology · doi:10.1159/000450946 · Cited by 35

Macro- and microvascular disease in systemic sclerosis

Kavian, N., & Batteux, F. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.05.015 · Cited by 37

Sarcoidosis-Associated Pulmonary Hypertension

Shlobin, O. A., & Baughman, R. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1603767 · Cited by 34

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis

Distler, O., Pope, J. E., Denton, C., Allanore, Y., Matucci‐Cerinic, M., Pena, J. D. O., & Khanna, D. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.09.011 · Cited by 34

New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy

Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Life · doi:10.3390/life11070610 · Cited by 34

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Tettey, A. T., Jiang, Y., Li, X., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.767002 · Cited by 36

An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition

Hu, L., Zhao, C., Chen, Z., Hu, G., Li, X., & Li, Q. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.011 · Cited by 34

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

Hoeper, M. M., Pausch, C., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H. J., Distler, O., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.03.011 · Cited by 34

Extending the translational potential of targeting NO/ cGMP ‐regulated pathways in the CVS

Papapetropoulos, A., Hobbs, A. J., & Topouzis, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12980 · Cited by 35

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow

Rogers, N. M., Seeger, F., Garcin, E. D., Roberts, D. D., & Isenberg, J. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00134 · Cited by 39

Treatment for Pulmonary Arterial Hypertension–Associated Right Ventricular Dysfunction

Gomez‐Arroyo, J. G., Sandoval, J., Simon, M. A. M., Dominguez-Cano, E., Voelkel, N. F., & Bogaard, H. J. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201312-425fr · Cited by 35

Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

Chazova, I. E., Martynyuk, T. V., Shmalts, A. A., Владимирович, Г. В., Danilov, N. M., Veselova, T. N., Захаровна, К. И., Шогаибович, С. А., Стукалова, О. В., Азизов, В. А., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-1-6-85 · Cited by 33

Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

Shen, Y.-H., Ding, D., Lian, T., Qiu, B., Yan, Y., Wang, P., Zhang, W., & Jing, Z. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.10.004 · Cited by 34

Emerging Therapies and Future Directions in Pulmonary Arterial Hypertension

Gurtu, V., & Michelakis, E. D. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.01.028 · Cited by 33

Update in systemic sclerosis-associated pulmonary arterial hypertension

Gashouta, M. A., Humbert, M. J. C., & Hassoun, P. M. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.06.007 · Cited by 33

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension

van Thor, M. C. J., ten Klooster, L., Snijder, R. J., Post, M. C., & Mager, J. J. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.02.004 · Cited by 33

Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease

Zimmer, D. P., Shea, C. M., Tobin, J. V., Tchernychev, B., Germano, P., Sykes, K., Banijamali, A. R., Jacobson, S., Bernier, S. G., Sarno, R., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00419 · Cited by 34

Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies

Spaczyńska-Kwiatkowska, M., Rocha, S. F., & Oliver, E. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00048 · Cited by 33

The future of heart failure with preserved ejection fraction

Heinzel, F. R., & Shah, S. J. (2022) · Herz · doi:10.1007/s00059-022-05124-8 · Cited by 36

Ion channels and transporters as therapeutic targets in the pulmonary circulation

Olschewski, A., Papp, R., Nagaraj, C., & Olschewski, H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.001 · Cited by 33

“Porto-pulmonary hypertension: A comprehensive review”

Liberal, R., Grant, C. R., Baptista, R., & Macedo, G. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.12.011 · Cited by 33

Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis

Moutchia, J., McClelland, R. L., Al‐Naamani, N., Appleby, D. H., Holmes, J. H., Minhas, J., Mazurek, J. A., Palevsky, H. I., Ventetuolo, C. E., & Kawut, S. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae049 · Cited by 32

The Endothelial ADMA/NO Pathway in Hypoxia-Related Chronic Respiratory Diseases

Lüneburg, N., Harbaum, L., & Hennigs, J. K. (2014) · BioMed Research International · doi:10.1155/2014/501612 · Cited by 32

Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications

Grześk, G., & Nowaczyk, A. (2021) · Molecules · doi:10.3390/molecules26113418 · Cited by 32

The Impact of Breathing Hypoxic Gas and Oxygen on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension

Carta, A. F., Lichtblau, M., Berlier, C., Saxer, S., Schneider, S., Schwarz, E. I., Furian, M., Bloch, K. E., & Ulrich, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.791423 · Cited by 32

Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension—Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Henrohn, D., Björkstrand, K., Lundberg, J. O., Granstam, S.-O., Baron, T., Ingimarsdóttir, I. J., Hedenström, H., Malinovschi, A., Wernroth, M.-L., Jansson, M., et al. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.09.010 · Cited by 32

Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy

Zhang, B., Enriquez-Sarano, M. L., Schaff, H. V., Michelena, H. I., Roos, C. M., Hagler, M. A., Zhang, H., Casaclang‐Verzosa, G., Huang, R., Bartoo, A. S., et al. (2025) · Circulation · doi:10.1161/circulationaha.123.066523 · Cited by 31

International Liver Transplantation Society practice guideline update on portopulmonary hypertension

DuBrock, H. M., Savale, L., Sitbon, O., Raevens, S., Kawut, S. M., Fallon, M. B., Heimbach, J. K., Chadha, R., Crespo, G., Ramsay, M. A. E., et al. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000600 · Cited by 31

Use of biologics and other novel therapies for the treatment of systemic sclerosis

Bruni, C., Praino, E., Allanore, Y., Distler, O., Gabrielli, A., Iannone, F., & Matucci‐Cerinic, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1263153 · Cited by 31

The Search for Disease-Modifying Therapies in Pulmonary Hypertension

Woodcock, C.-­. C., & Chan, S. Y. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419829172 · Cited by 31

Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization

Atsukawa, M., Tsubota, A., Hatano, M., Kondo, C., Shioda, K., Ohno, H., Kawano, T., Hayama, K., Arai, T., Nakagawa‐Iwashita, A., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13560 · Cited by 31

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways

Mandras, S. A., Kovács, G., Olschewski, H., Broderick, M. J., Nelsen, A. C., Shen, E., & Champion, H. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211006531 · Cited by 33

Implications of Mean Pulmonary Arterial Wedge Pressure Trajectories in Pulmonary Arterial Hypertension

Harder, E. M., Divo, M. J., Washko, G. R., Leopold, J. A., Rahaghi, F. N., & Waxman, A. B. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202306-1072oc · Cited by 31

Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics.

Frank, D. B., & Hanna, B. D. (2015) · PubMed · Cited by 31

Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension

Segura-Ibarra, V., Wu, S., Hassan, N., Moran-Guerrero, J. A., Mauro Ferrari, B., Guha, A., Karmouty‐Quintana, H., & Blanco, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00890 · Cited by 31

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation

Mauersberger, C., Sager, H., Wobst, J., Dang, T., Lambrecht, L., Koplev, S., Stroth, M., Bettaga, N., Schlossmann, J., Wunder, F., et al. (2021) · bioRxiv · doi:10.1038/s44161-022-00175-w · Cited by 28

Pulmonary Arterial Hypertension

Barnett, C. F., Alvarez, P. A., & Park, M. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.04.006 · Cited by 30

Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities

Badlam, J. B., & Bull, T. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317693218 · Cited by 30

Emerging therapeutics in pulmonary hypertension

Hensley, M. K., Levine, A. R., Gladwin, M. T., & Lai, Y. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00259.2017 · Cited by 30

A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects

Hanrahan, J. P., WAKEFIELD, J. D., Wilson, P. J., Mihova, M., Chickering, J. G., Ruff, D. A., Hall, M., Milne, G. T., Currie, M. G., & Profy, A. T. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.627 · Cited by 30

Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features

Navarro-Vergara, D.-I., Roldán-Valadéz, E., Cueto‐Robledo, G., & Jurado-Hernandez, M. Y. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100747 · Cited by 30

Systemic sclerosis in adults. Part II: management and therapeutics

Jerjen, R., Nikpour, M., Krieg, T. M., Denton, C. P., & Saracino, A. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.10.066 · Cited by 30

Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis

Pitre, T., Su, J. S., Cui, S., Scanlan, R., Chiang, C., Husnudinov, R., Khalid, M. F., Khan, N., Leung, G., Mikhail, D., et al. (2022) · European Respiratory Review · doi:10.1183/16000617.0036-2022 · Cited by 32

Parameter inference in a computational model of haemodynamics in pulmonary hypertension

Colunga, A. L., Colebank, M. J., Program, R., & Olufsen, M. S. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0735 · Cited by 33

Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension

Zhang, R., Wang, X., Zhang, H., Sun, X., Zhao, Q., Wang, L., He, J., Jiang, X., Liu, J., & Jing, Z. (2016) · European Respiratory Journal · doi:10.1183/13993003.00245-2016 · Cited by 31

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Nagaraja, V., Spino, C., Bush, E., Tsou, P., Domsic, R. T., Lafyatis, R., Frech, T., Gordon, J., Steen, V. D., & Khanna, D. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1979-7 · Cited by 30

Riociguat for Pulmonary Hypertension

Ghofrani, H. A., Simonneau, G., & Rubin, L. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1312903 · Cited by 30

Update on pulmonary arterial hypertension pharmacotherapy

Velayati, A., Valerio, M. G., Shen, M., Tariq, S., Lanier, G. M., & Aronow, W. S. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1188664 · Cited by 29

Pulmonary arterial hypertension – progress in understanding the disease and prioritizing strategies for drug development

Ghataorhe, P., Rhodes, C. J., Harbaum, L., Attard, M., Wharton, J., & Wilkins, M. R. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12623 · Cited by 29

EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension

Lai, Y., Chen, I.-C., Li, H.-H., & Huang, C.-C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030727 · Cited by 29

Drug repositioning in pulmonary arterial hypertension: challenges and opportunities

Grinnan, D., Trankle, C. R., Andruska, A., Bloom, B. E., & Spiekerkoetter, E. F. (2019) · Pulmonary Circulation · doi:10.1177/2045894019832226 · Cited by 32

Guanylyl Cyclase Activation Reverses Resistive Breathing–Induced Lung Injury and Inflammation

Glynos, C., Toumpanakis, D., Loverdos, K., Karavana, V. N., Zhou, Z., Μagkou, C., Dettoraki, M., Perlikos, F., Pavlidou, A., Kotsikoris, V., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0092oc · Cited by 29

Pulmonary hypertension: diagnostic approach and optimal management

Hambly, N., Alawfi, F., & Mehta, S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151075 · Cited by 30

Pulmonary hypertension in patients with interstitial lung disease

Karampitsakos, Τ., Tzouvelekis, A., Chrysikos, S., Bouros, D. E., Tsangaris, I., & Fares, W. H. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.03.002 · Cited by 29

Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases

Dorschel, K. B., & Wanebo, J. E. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.661611 · Cited by 29

Current Treatment Approaches to Pulmonary Arterial Hypertension

Provencher, S., & Granton, J. T. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.10.024 · Cited by 28

Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam

Becker, C., Frey, R., Unger, S., Thomas, D., Reber, M., Weimann, G., Dietrich, H., Arens, E. R., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685016 · Cited by 28

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up

Xanthouli, P., Kögler, M., Marra, A. M., Benjamin, N., Fischer, L., Eichstaedt, C. A., Harutyunova, S., Nagel, C., Grünig, E., & Egenlauf, B. (2020) · Respiratory Research · doi:10.1186/s12931-020-01393-1 · Cited by 28

Atualização no Tratamento da Hipertensão Arterial Pulmonar

Fernandes, C. J. C. D. S., Calderaro, D., Assad, A. P. L., Salibe-Filho, W., Morinaga, L. T. K., Hoette, S., Piloto, B. M., Castro, M. A., Lisboa, R. P., da Silva, T. A. F., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200702 · Cited by 28

An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients

Ruaro, B., Salton, F., Baratella, E., Confalonieri, P., Geri, P., Pozzan, R., Torregiani, C., Bulla, R., Confalonieri, M., Matucci‐Cerinic, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030616 · Cited by 28

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

McLaughlin, V. V., Jansa, P., Nielsen‐Kudsk, J. E., Halank, M., Simonneau, G., Grünig, E., Ulrich, S., Rosenkranz, S., Sánchez, M. Á. G., Pulido, T., et al. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0563-7 · Cited by 28

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling

Lyapina, I. N., Андреевна, Б. А., Saidova, M. A., Martynyuk, T. V., & Chazova, I. E. (2018) · Lung · doi:10.1007/s00408-018-0160-4 · Cited by 28

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63‐2521)

Frey, R., Becker, C., Unger, S., Schmidt, A., Wensing, G., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685017 · Cited by 27

Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

Hobbs, A. J., Moyes, A. J., Baliga, R. S., Ghedia, D., Ochiel, R., Sylvestre, Y., Doré, C. J., Chowdhury, K., Maclagan, K., Quartly, H., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14621 · Cited by 27

Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling

Li, T., Li, S., Feng, Y., Zeng, X., Dong, S., Li, J., Zha, L., Luo, H., Zhao, L., Liu, B., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6973636 · Cited by 27

Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension

Ho, L., Hossen, M. N., Nguyen, T. B., Vo, A., & Ahsan, F. (2022) · Biomedicines · doi:10.3390/biomedicines10010170 · Cited by 27

Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience

Mercier, O. M., Dubost, C., Delaporte, A., Genty, T., Fabre, D., Mitilian, D., Girault, A., Issard, J., Astaneh, A., Ménager, J.-B., et al. (2022) · Annals of Cardiothoracic Surgery · doi:10.21037/acs-2021-pte-20 · Cited by 27

What’s new in the treatment of portopulmonary hypertension?

DuBrock, H. M., Channick, R. N., & Krowka, M. J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1035647 · Cited by 27

The Burden of Pulmonary Hypertension in Resource-Limited Settings

Gidwani, S., & Nair, A. P. (2014) · Global Heart · doi:10.1016/j.gheart.2014.08.007 · Cited by 27

Diagnosis and Management of Systemic Sclerosis: A Practical Approach

Lee, J. J., & Pope, J. E. (2015) · Drugs · doi:10.1007/s40265-015-0491-x · Cited by 27

New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension

Hill, N. S., Cawley, M. J., & Heggen, C. L. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.3-a.s3 · Cited by 27

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study

Galiè, N., Grimminger, F., Grünig, E., Hoeper, M. M., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Rubin, L. J., Fritsch, A., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.12.012 · Cited by 27

＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment.

Kondo, T., Okumura, N., Adachi, S., & Murohara, T. (2019) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.81.1.19 · Cited by 27

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63‐2521)

Frey, R., Becker, C., Unger, S., Schmidt, A., Wensing, G., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685015 · Cited by 27

Editorial Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Kurzyna, M., Darocha, S., Koteja, A., Pietura, R., & Torbicki, A. (2015) · Advances in Interventional Cardiology · doi:10.5114/pwki.2015.49176 · Cited by 27

Treatment-Related Biomarkers in Pulmonary Hypertension

Swaminathan, A. C., Dusek, A. C., & McMahon, T. J. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0438tr · Cited by 26

Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits

Green, S., & Stuart, D. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa001 · Cited by 26

Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Benza, R. L., Ghofrani, H.-A., Grünig, E., Hoeper, M. M., Jansa, P., Jing, Z., Kim, N. H., Langleben, D., Simonneau, G., Wang, C., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.06.020 · Cited by 26

Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction: Differential Diagnosis and Management

Hussain, N., Charalampopoulos, A. F., Ramjug, S., Condliffe, R. A., Elliot, C. A., O’Toole, L., Swift, A. J., & Kiely, D. G. (2016) · Pulmonary Circulation · doi:10.1086/685021 · Cited by 26

Pulmonary Arterial Hypertension in Women

Memon, H. A., & Park, M. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-224 · Cited by 26

Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease

del Valle, K. T., & DuBrock, H. M. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210009 · Cited by 26

Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs

Wang, J. J., Jin, S., Zhang, H., Xu, Y., Hu, W., Jiang, Y., Chen, C., Wang, D. W., Xu, H. E., & Wu, C. (2024) · Science Advances · doi:10.1126/sciadv.adk5184 · Cited by 25

Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course

Fuso, L., Baldi, F., Arrighi, E., & Valente, S. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s48920 · Cited by 25

Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso‐occlusion and nephropathy in mouse models of sickle cell disease

Tchernychev, B., Li, H., Lee, S. K., Gao, X., Ramanarasimhaiah, R., Liu, G., Hall, K. C., Bernier, S. G., Jones, J. E., Feil, S. C., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15492 · Cited by 25

MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment

Wołowiec, Ł., Mędlewska, M., Osiak, J., Wołowiec, A., Grześk, E., Jaśniak, A., & Grześk, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119735 · Cited by 25

Medical treatment update on pulmonary arterial hypertension

Enderby, C. Y., & Burger, C. D. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315590757 · Cited by 25

Redox Biology in Pulmonary Arterial Hypertension (2013 Grover Conference Series)

Fessel, J. P., & West, J. D. (2015) · Pulmonary Circulation · doi:10.1086/683814 · Cited by 25

New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

Mercurio, V., Bianco, A., Campi, G., Cuomo, A., Diab, N., Mancini, A., Parrella, P., Petretta, M., Hassoun, P. M., & Bonaduce, D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180201095743 · Cited by 25

Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension

Khirfan, G., Tejwani, V., Wang, X., Li, M., DiDonato, J. A., Dweik, R. A., Smedira, N. G., & Heresi, G. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197700 · Cited by 25

Treatment of pediatric pulmonary arterial hypertension: A focus on the NO‐sGC‐cGMP pathway

Beghetti, M., Gorenflo, M., Ivy, D. D., Moledina, S., & Bonnet, D. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24442 · Cited by 25

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221

Riociguat for the Treatment of Pulmonary Hypertension: A Meta-analysis of Randomized Controlled Trials

Alrifai, A., Garnet, B., Shah, V., & Lit, L. (2015) · CHEST Journal · doi:10.1378/chest.2281793

Riociguat in Combination With Endothelin Receptor Antagonists (ERAs) for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of PATENT

Hill, N. S., & Sood, N. (2015) · CHEST Journal · doi:10.1378/chest.2281116

September 2013 pulmonary journal club: riociguat; pay the doctor

Robbins, R. (2013) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc116-13

Influence of riociguat treatment on pulmonary arterial hypertension

Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8